- Conditions
- Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ, No Evidence of Disease
- Interventions
- Oxybutynin Chloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 13
- States / cities
- Peoria, Illinois • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 51
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sleep Apnea
- Interventions
- Atomoxetine, Oxybutynin, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Overactive Bladder
- Interventions
- trospium chloride, oxybutynin IR, oxybutynin IR placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Detrusor Hyperreflexia
- Interventions
- Oxybutynin
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 15 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Orange County, California • San Diego, California + 20 more
- Conditions
- Healthy
- Interventions
- Oxybutynin Chloride Gel, Placebo Gel
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Overactive Bladder
- Interventions
- solabegron and oxybutynin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Healthy
- Interventions
- Oxybutynin Chloride ER Tablets 10 mg, Ditropan XL® Tablets 10 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Overactive Detrusor, Neurogenic Bladder
- Interventions
- Oxybutynin, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 3 Years to 16 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 10
- States / cities
- Loma Linda, California • Orange, California • Aurora, Colorado + 7 more
- Conditions
- Obstructive Sleep Apnea, Down Syndrome
- Interventions
- Atomoxetine and oxybutynin (ato-oxy)
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Healthy
- Interventions
- Oxybutynin Chloride ER Tablets 10 mg, Ditropan XL® Tablets 10 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Healthy Volunteers
- Interventions
- Darifenacin, Oxybutynin, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 150 participants
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Urinary Bladder, Neurogenic
- Interventions
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg, Fesoterodine BIC 4 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more
- Conditions
- Healthy
- Interventions
- Oxybutynin Chloride Extended-release Tablets 5 mg, Ditropan XL® Tablets 5 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Urge Urinary Incontinence, Urinary Frequency
- Interventions
- Oxybutynin, Placebo
- Drug
- Lead sponsor
- Antares Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Laguna Hills, California + 50 more
- Conditions
- Overactive Bladder
- Interventions
- Oxybutynin topical gel, Placebo topical gel
- Drug · Other
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 789 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more
- Conditions
- Hyperhidrosis
- Interventions
- Oxybutynin 3% gel
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Urinary Incontinence, Urge
- Interventions
- Anticholinergic medications, Hypnotherapy
- Drug · Behavioral
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Parkinson's Disease, Overactive Bladder
- Interventions
- Oxybutynin and darifenacin
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Overactive Bladder
- Interventions
- Behavioral training, Oxybutynin chloride, extended-release
- Behavioral · Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 19 Years and older · Male only
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Decatur, Georgia
- Conditions
- Sialorrhoea
- Interventions
- oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C, oxybutynin and clonidine oral solution treatment D
- Drug
- Lead sponsor
- Orient Pharma Co., Ltd.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Bingham Farms, Michigan
- Conditions
- Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
- Interventions
- Multimodal Bundle Drugs, Operative Cystoscopy, Behavioral health consultation/therapy, Pelvic floor physical therapy, Usual Urogynecologic care, Bladder Instillation, Vaginal estrogen, Methenamine, Amitriptyline/Gabapentin
- Drug · Procedure · Behavioral + 1 more
- Lead sponsor
- Jocelyn Fitzgerald
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Overactive Bladder
- Interventions
- Oxybutynin (Oxytrol, BAY839380)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 855 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Saint Joseph, Missouri
- Conditions
- Obstructive Sleep Apnea, Sleep-disordered Breathing
- Interventions
- Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition
- Other · Device · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hot Flashes
- Interventions
- Fezolinetant, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 39 more